Panacea Biotec, India's second largest vaccine producer, finds itself in an unenviable financial position with substantial net worth erosion, highlighting what some experts say are the perils of dependence on "binary" tender-based bulk purchases.

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.